Examples are systemic interferon (IFN)-α treatment that increased sHLA-G serum and sHLA-I plasma levels in melanoma and chronic myeloid leukemia (CML), respectively [52,75]. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.